Phaseline

Companies › Praxis Precision Medicines

Praxis Precision Medicines: clinical trials, targets and expected readouts

6 active drug programs in 7 registered trials: 4 Phase 3, 2 Phase 2, 1 Phase 1; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
elsunersen
antisense oligonucleotide targeting SCN2A
Ion channelsPhase 3Epileptic EncephalopathyDec 2026
relutrigine (PRAX-562)
NMDA receptor antagonist; selective GluN2B-containing NMDA receptor inhibitor
GRIN2BPhase 3Developmental and Epileptic Encephalopathy 1; SCN2A EncephalopathyDec 2026
vormatrigine
Sodium channel modulator
–Phase 3Focal EpilepsyJan 2027
ulixacaltamide
NMDA receptor antagonist (GluN2B subunit selective)
GRIN2BPhase 3Essential TremorMar 2027
PRAX-628–Phase 2Focal Onset Seizure–
PRAX-222
Selective sodium channel modulator targeting SCN2A mutations
Ion channelsPhase 1SCN2A-DEEFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06908356PRAX-628Phase 2Focal Onset SeizureNeurologyJul 2025
NCT07010471relutrigine (PRAX-562)Phase 3Developmental and Epileptic Encephalopathy 1NeurologyDec 2026
NCT07019922elsunersenPhase 3Epileptic EncephalopathyNeurologyDec 2026
NCT07505004vormatriginePhase 3Focal EpilepsyNeurologyJan 2027
NCT05818553relutrigine (PRAX-562)Phase 2SCN2A EncephalopathyNeurologyMar 2027
NCT06087276ulixacaltamidePhase 3Essential TremorNeurologyMar 2027
NCT05737784PRAX-222Phase 1SCN2A-DEENeurologyFeb 2028

From the company's SEC filings

Cash and short-term investments of $1.3bn on 2026-09-30; operating cash outflow about $329m a year; runway about 47 months at that burn, to Sep 2030; 5 of 5 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

Ion channels (2) GRIN2B (2)

Companies with the same targets

Xenon Pharmaceuticals HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine Industrial Farmacéutica Cantabria

Companies built like this

Actio Biosciences Aptinyx SHINKEI Therapeutics Xenon Pharmaceuticals Ionis Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.